Fatty acid based hyperbranched polymeric nanoparticles for hydrophobic drug delivery

A Comprehensive Review on Processing, Development and Applications of Organofunctional Silanes and Silane-Based Hyperbranched Polymers

Since the last decade, hyperbranched polymers (HBPs) have gained wider theoretical interest and practical applications in sensor technology due to their ease of synthesis, highly branched structure but dimensions within nanoscale, a larger number of modified terminal groups and lowering of viscosity in polymer blends even at higher HBP concentrations. Many researchers have reported the synthesis of HBPs using different organic-based core-shell moieties. Interestingly, silanes, as organic-inorganic hybrid modifiers of HBP, are of great interest as they resulted in a tremendous improvement in HBP properties like increasing thermal, mechanical and electrical properties compared to that of organic-only moieties. This review focuses on the research progress in organofunctional silanes, silane-based HBPs and their applications since the last decade. The effect of silane type, its bi-functional nature, its influence on the final HBP structure and the resultant properties are covered in detail. Methods to enhance the HBP properties and challenges that need to be overcome in the near future are also discussed.

Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate

BACKGROUND

Expression of human epidermal growth factor receptor type 2 (HER2) in head and neck squamous cell carcinoma (HNSCC) cell line HN5 can be employed with great opportunities of success for specific targeting of anti-cancer chemotherapeutic agents.

OBJECTIVE

In the current study, HER2-specific affibody molecule, ZHER2:342 (an engineered protein with great affinity for HER2 receptors) was selected for conjugation to idarubicin (an anti-neoplastic antibiotic).

METHOD

ZHER2:342 affibody gene with one added cysteine code at the its 5' end was synthesized de novo and then inserted into pET302 plasmid and transferred to E. Coli BL21 hosting system. After induction of protein expression, the recombinant ZHER2 affibody molecules were purified using Ni- NTA resin and purity was analyzed through SDS-PAGE. Affinity-purified affibody molecules were conjugated to idarubicin through a heterobifunctional crosslinker, sulfosuccinimidyl 4-(Nmaleimidomethyl) cyclohexane-1-carboxylate (Sulfo-SMCC). Specific toxicity of idarubicin-ZHER2 affibody conjugate against two HER2-positive cells, HN5 and MCF-7 was assessed through MTT assay after an exposure time of 48 hours with different concentrations of conjugate.

RESULTS

Idarubicin in the non-conjugated form showed potent toxic effects against both cell lines, while HN5 cells were significantly more sensitive compared to MCF-7 cells. Dimeric ZHER2 affibody showed a mild decreasing effect on growth of both HN5 and MCF-7 cells at optimum concentration. Idarubicin-ZHER2 affibody conjugate at an optimum concentration reduced viability of HN5 cell line more efficiently compared to MCF-7 cell line.

CONCLUSION

In conclusion, idarubicin-ZHER2 affibody conjugate in optimum concentrations can be used for specific targeting and killing of HN5 cells.